Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Serina Therapeutics (SER) Gross Margin (2018 - 2023)

Serina Therapeutics' Gross Margin history spans 6 years, with the latest figure at 1.78% for Q4 2023.

  • For Q4 2023, Gross Margin fell 8572.0% year-over-year to 1.78%; the TTM value through Dec 2023 reached 3.24%, down 5853.0%, while the annual FY2023 figure was 3.24%, 5853.0% down from the prior year.
  • Gross Margin for Q4 2023 was 1.78% at Serina Therapeutics, down from 117.24% in the prior quarter.
  • Across five years, Gross Margin topped out at 117.24% in Q3 2023 and bottomed at 1.78% in Q4 2023.
  • The 5-year median for Gross Margin is 85.83% (2019), against an average of 75.76%.
  • The largest YoY upside for Gross Margin was 7280bps in 2023 against a maximum downside of -8572bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 85.61% in 2019, then grew by 6bps to 90.62% in 2020, then grew by 6bps to 96.3% in 2021, then decreased by -9bps to 87.5% in 2022, then crashed by -98bps to 1.78% in 2023.
  • Per Business Quant, the three most recent readings for SER's Gross Margin are 1.78% (Q4 2023), 117.24% (Q3 2023), and 57.14% (Q2 2023).